IP Verse

Improved Methods For Preparing Squalene - EP3489211

The patent EP3489211 was granted to Novartis on Jul 15, 2020. The application was originally filed on May 12, 2011 under application number EP19151232A. The patent is currently recorded with a legal status of "Revoked".

EP3489211

NOVARTIS
Application Number
EP19151232A
Filing Date
May 12, 2011
Status
Revoked
Jan 18, 2025
Grant Date
Jul 15, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GLAXOSMITHKLINEApr 15, 2021FURSTOSSADMISSIBLE

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20100395448-
DESCRIPTIONEP0139417
DESCRIPTIONEP0520618
DESCRIPTIONUS2007014805
DESCRIPTIONUS2007191314
DESCRIPTIONUS4060082
DESCRIPTIONUS5971953
DESCRIPTIONUS6692468
DESCRIPTIONWO0007647
DESCRIPTIONWO0122992
DESCRIPTIONWO02097072
DESCRIPTIONWO2005089837
DESCRIPTIONWO2007052155
DESCRIPTIONWO2008043774
DESCRIPTIONWO9014837
DESCRIPTIONWO9737000
DESCRIPTIONWO9801174
DESCRIPTIONWO9917820
OPPOSITIONCN101597204
OPPOSITIONCN1810744
OPPOSITIONJPS6116171
OPPOSITIONWO2008043774
OPPOSITIONWO2008142175
OPPOSITIONWO2010004193
SEARCHJPH06116171

Non-Patent Literature (NPL) Citations (45) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BANZHOFF, Immunology Letters, (20000000), vol. 71, pages 91 - 96-
DESCRIPTION- BERTONE et al., J Fish Diseases, (19960000), vol. 19, pages 429 - 34-
DESCRIPTION- BORUCINSKA; FRASCA, J Fish Diseases, (20020000), vol. 25, pages 287 - 98-
DESCRIPTION- BRANDS et al., Dev Biol Stand, (19990000), vol. 98, pages 93 - 100-
DESCRIPTION- BRIONES et al., J Vet Med B, (19980000), vol. 45, pages 443 - 5-
DESCRIPTION- BRUHL et al., Vaccine, (20000000), vol. 19, pages 1 149 - 58-
DESCRIPTION- CHEN et al., Vaccine, (20030000), vol. 21, pages 2830 - 6-
DESCRIPTION- DEMICHELI et al., Vaccine, (19980000), vol. 16, pages 880 - 884-
DESCRIPTION- GREENBAUM et al., Vaccine, (20040000), vol. 22, pages 2566 - 77-
DESCRIPTION- HALPERIN et al., Am J Public Health, (19790000), vol. 69, pages 1247 - 50-
DESCRIPTION- HALPERIN et al., Vaccine, (20020000), vol. 20, pages 1240 - 7-
DESCRIPTION- HARPER et al., Lancet, (20040000), vol. 364, no. 9447, pages 1757 - 65-
DESCRIPTION- HEHME et al., Virus Res., (20040000), vol. 103, no. 1-2, pages 163 - 71-
DESCRIPTION- HERBERT et al., J Infect Dis, (19790000), vol. 140, pages 234 - 8-
DESCRIPTION- HOFFMANN et al., Vaccine, (20020000), vol. 20, pages 3 165 - 3170-
DESCRIPTION- J Toxicol Clin Toxicol, (20010000), vol. 39, pages 85 - 100-
DESCRIPTION- KEITEL et al., Clin Diagn Lab Immunol, (19960000), vol. 3, pages 507 - 10-
DESCRIPTION- KISTNER et al., Dev Biol Stand, (19990000), vol. 98, pages 101 - 110-
DESCRIPTION- KISTNER et al., Vaccine, (19980000), vol. 16, pages 960 - 8-
DESCRIPTION- LIU et al., Virology, (20030000), vol. 314, pages 580 - 590-
DESCRIPTION- LOUKAS et al., PLoS Med, (20050000), vol. 2, no. 10, page e295-
DESCRIPTION- MANN et al., Vaccine, (20040000), vol. 22, pages 2425 - 9-
DESCRIPTION- OZAKI et al., J. Virol., (20040000), vol. 78, pages 1851 - 1857-
DESCRIPTION- PAU et al., Vaccine, (20010000), vol. 19, pages 2716 - 21-
DESCRIPTION- PIASCIK, JAm Pharm Assoc (Wash DC), (20030000), vol. 43, pages 728 - 30-
DESCRIPTION- PODDA; DEL GIUDICE, Expert Rev Vaccines, (20030000), vol. 2, pages 197 - 203-
DESCRIPTION- PODDA, Vaccine, (20010000), vol. 19, pages 2673 - 2680-
DESCRIPTION- STEPANOV et al., J Biotechnol, (19960000), vol. 44, pages 155 - 160-
DESCRIPTION- SUBBARAO et al., Virology, (20030000), vol. 305, pages 192 - 200-
DESCRIPTION- SULI et al., Vaccine, (20040000), vol. 22, no. 25-26, pages 3464 - 9-
DESCRIPTION- TREANOR et al., J Infect Dis, (19960000), vol. 173, pages 1467 - 70-
DESCRIPTION- TREE et al., Vaccine, (20010000), vol. 19, pages 3444 - 50-
DESCRIPTION- "Vaccine Adjuvants: Preparation Methods and Research Protocols", Methods in Molecular Medicine series, vol. 42-
DESCRIPTION- WEBBY et al., Lancet, (20040000), vol. 363, pages 1099 - 11 03-
DESCRIPTION- WILLIAMSON et al., Infection and Immunity, (20060000), vol. 74, pages 961 - 7-
DESCRIPTION- ZURBRIGGEN et al., Expert Rev Vaccines, (20030000), vol. 2, pages 295 - 304-
OPPOSITION- Anonymous, "CHMP Assessment Report for Focetria - Pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) A/California/7/2009 H1Hv like strain (X-179a)", European Medicines Agency, (20090924), pages 1 - 56, XP055962135-
OPPOSITION- Anonymous, "Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008", ClinicalTrials.gov Identifier: NCT01333462, (20120412), pages 1 - 8, URL: https://clinicaltrials.gov/ct2/show/study/NCT01333462, XP055962176-
OPPOSITION- Anonymous, "Vacuum distillation", Wikipedia, (20090506), pages 1 - 3, URL: http://en.wikipedia.org/w/index.php?title=VacuumdIstillation&oldid=288287808, XP055962147-
OPPOSITION- PIETSCH et al., "Concentration of squalene from shark liver oil by short-path distillation", Eur. J. Lipid Sci. Technol., (20070000), vol. 109, doi:10.1002/ejlt.200700039, pages 1077 - 1082, XP055055506
OPPOSITION- FOX et al., "Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions", Colloids and Surfaces B: Biointerfaces, (20080000), vol. 65, doi:10.1016/j.colsurfb.2008.03.003, pages 98 - 105, XP022710121
OPPOSITION- BRITO et al., "An alternative renewable source of squalene for use in emulsion adjuvants", Vaccine, (20110000), vol. 29, no. 37, doi:10.1016/j.vaccine.2011.06.067, pages 66262 - 6268, XP028263655
OPPOSITION- STANBERRY et al., "Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805 EC combined with approved seasonal influenza antigens", Vaccine, (20110000), vol. 30, no. 2, doi:10.1016/j.vaccine.2011.10.094, pages 307 - 316, XP028348279
OPPOSITION- Makidon Paul E., Bielinska Anna U., Nigavekar Shraddha S., Janczak Katarzyna W., Knowlton Jessica, Scott Alison J., Mank Nicholas, Cao Zhengyi, Rathinavelu Sivaprakash, Beer Michael R., Wilkinson J. Erby, Blanco Luz P., Landers Jeffrey J., Baker James R., "Pre-clinical Evaluation of a Novel Nanoemulsion-based Hepatitis B Mucosal Vaccine", PLoS ONE, (20080000), vol. 3, no. Issue 8, pages E2954.1 - E2954.15, XP002676516
SEARCH- ARNE PIETSCH ET AL, "Concentration of squalene from shark liver oil by short-path distillation", EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, (20071101), vol. 109, no. 11, doi:10.1002/ejlt.200700039, ISSN 1438-7697, pages 1077 - 1082, XP055055506 [A] 1-19 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents